984 related articles for article (PubMed ID: 16156884)
1. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
2. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
4. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
6. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
7. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
Ena J; Leach A; Nguyen P
HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
9. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
10. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
11. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
13. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
15. Experience with nevirapine in previously treated HIV-1-infected individuals.
Wit FW;
Antivir Ther; 2000 Dec; 5(4):257-66. PubMed ID: 11142620
[TBL] [Abstract][Full Text] [Related]
16. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
20. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
